Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) EBT Margin (2020 - 2025)

Apellis Pharmaceuticals has reported EBT Margin over the past 6 years, most recently at 101.68% for Q4 2025.

  • Quarterly results put EBT Margin at 101.68% for Q4 2025, down 9539.0% from a year ago — trailing twelve months through Dec 2025 was 12.01% (up 1026.0% YoY), and the annual figure for FY2025 was 12.01%, up 1026.0%.
  • EBT Margin for Q4 2025 was 101.68% at Apellis Pharmaceuticals, down from 47.17% in the prior quarter.
  • Over the last five years, EBT Margin for APLS hit a ceiling of 1770.4% in Q4 2022 and a floor of 35183.15% in Q2 2021.
  • Median EBT Margin over the past 5 years was 59.54% (2023), compared with a mean of 2111.31%.
  • Biggest five-year swings in EBT Margin: soared 3423050bps in 2022 and later tumbled -182994bps in 2023.
  • Apellis Pharmaceuticals' EBT Margin stood at 470.64% in 2021, then surged by 276bps to 1770.4% in 2022, then plummeted by -103bps to 59.54% in 2023, then skyrocketed by 89bps to 6.29% in 2024, then crashed by -1517bps to 101.68% in 2025.
  • The last three reported values for EBT Margin were 101.68% (Q4 2025), 47.17% (Q3 2025), and 23.35% (Q2 2025) per Business Quant data.